TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A meta-analysis of 85 randomized trials involving 70,543 people found that SGLT2 inhibitor treatment was associated with higher hemoglobin and hematocrit than control treatment over a median 24 weeks. The results also showed changes in several measures related to red blood cell production and iron; whether these changes improve anemia or contribute to other treatment benefits remains uncertain.
A review of 85 randomized clinical trials found that SGLT2 inhibitors were associated with modest increases in hemoglobin and hematocrit across patients with kidney disease, heart failure, type 2 diabetes and cardiovascular disease. The analysis, involving 70,543 participants, was presented at the American Society of Nephrology Kidney Week meeting and published in JAMA; it does not establish that the blood changes improve anemia or explain the drugs’ broader health effects.
Over a median follow-up of 24 weeks, hemoglobin rose by an average of 0.55 grams per deciliter in SGLT2 inhibitor groups and fell by 0.08 g/dL in control groups. The estimated difference between groups was 0.60 g/dL (95% confidence interval 0.55 to 0.66; P<0.001). Hematocrit rose by 2.17 percentage points with treatment and declined by 0.13 points in control groups, a between-group difference of 2.36 percentage points (95% CI 2.19 to 2.52; P<0.001).
The review also found changes in several secondary measures. Erythropoietin, a hormone involved in red blood cell production, increased by 2.35 mIU/mL in treatment groups versus 0.04 mIU/mL in controls. Red blood cell concentration increased more with treatment, while ferritin and transferrin saturation decreased. Changes in hepcidin and serum iron did not meet the analysis’s threshold for statistical significance.
Lead author Michele F. Eisenga of University Medical Center Groningen said the pattern suggests the rise in hemoglobin may involve more than fluid-related concentration of the blood. The analysis included trials of several SGLT2 inhibitors, most commonly empagliflozin and dapagliflozin. The authors also reported post hoc findings suggesting larger hemoglobin differences at higher doses and longer follow-up; these analyses do not by themselves establish how dose or treatment duration should be selected.
Potential Relevance to Anemia Care
The findings may matter for patients with chronic kidney disease or heart failure, conditions in which anemia can be a concern, and for clinicians monitoring blood counts during SGLT2 inhibitor treatment. The authors said the modest hemoglobin rise could potentially contribute to anemia management. In an accompanying editorial, Kai-Uwe Eckardt and Mark J. Koury wrote that there are reasons to think the change could help, while emphasizing the evidence gaps.
The results do not show that SGLT2 inhibitors should be prescribed as anemia treatments, nor that patients should alter an existing prescription. The review measured changes in laboratory outcomes across trials; it did not demonstrate that those changes directly improved anemia symptoms, reduced the need for standard anemia therapies or caused the drugs’ benefits for heart and kidney outcomes. The authors said future studies need to test those possibilities.
There is also a safety question for people whose hemoglobin or hematocrit is already elevated. The authors cautioned that further increases could potentially raise the risk of thromboembolic events. The meta-analysis, as described in the report, does not settle the size of that risk or identify which patients might be most affected.
Products Worth Considering
Withings BPM Connect Smart Blood Pressure Monitor
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Oral-B iO Series 7 Rechargeable Electric Toothbrush with 2 Brush Heads and Charging Travel Case
As an affiliate, we earn on qualifying purchases.
What the Trials Measured
The analysis pooled double-blind randomized trials in which SGLT2 inhibitors were used alone or alongside other treatment. Participants had chronic kidney disease, heart failure, type 2 diabetes, cardiovascular disease, or combinations of these conditions. Their mean age was 62.4 years; 35.9% were female. Average hemoglobin at baseline was 13.6 g/dL and average hematocrit was 41.5%.
Earlier explanations for rising hemoglobin and hematocrit focused on hemoconcentration, or a higher concentration of blood components as fluid volume changes. Eisenga told MedPage Today that the accompanying increases in erythropoietin and changes in iron-related measures fit a broader effect on red blood cell production and iron metabolism. That is an interpretation of the pattern, not a direct measurement of the processes involved.
The editorial authors noted that hemoglobin increases reached a maximum only at 48 weeks in earlier observations, a time course they said may fit gradual adjustment of red blood cell production better than persistent fluid contraction. They also stressed that the trials offered limited data on red blood cell indices and did not report direct measurements of red blood cell mass, plasma volume or red blood cell lifespan.
“This is the largest and most comprehensive analysis to date of the effects of SGLT2 inhibitors on hematologic and iron-related parameters.”
— Michele F. Eisenga, lead author, speaking to MedPage Today
Mechanism and Patient Risks
The trials did not directly measure red blood cell mass, plasma volume or red blood cell lifespan, so the analysis cannot confirm exactly why hemoglobin and hematocrit rose. The erythropoietin and iron-related findings offer clues, but they do not prove a specific biological pathway.
It is also unclear whether the laboratory changes lead to better anemia-related outcomes, directly contribute to cardiorenal benefits, or reduce use of conventional anemia treatments. The authors called for future trials to test those questions. The report also raises a possible clotting concern for patients who start with high hemoglobin or hematocrit, but does not quantify the risk or establish how it should affect individual care.
Questions for Future Trials
Future studies will need to connect changes in blood counts with patient outcomes, including anemia symptoms, use of conventional anemia therapies and heart or kidney benefits. Researchers could also measure red blood cell mass and related factors directly to distinguish changes in red cell production from shifts in blood volume.
For now, the findings describe an average effect across varied trial populations and follow-up periods, not a treatment recommendation for an individual. Patients taking an SGLT2 inhibitor should discuss concerns about blood counts or treatment changes with their clinician. The available report does not specify a new monitoring schedule or a clinical threshold for action.
Key Questions
How much did hemoglobin increase with SGLT2 inhibitors?
Across the trials, hemoglobin rose by an average of 0.55 g/dL in SGLT2 inhibitor groups and fell by 0.08 g/dL in control groups over a median of 24 weeks. The estimated difference between groups was 0.60 g/dL.
Does this study show that SGLT2 inhibitors treat anemia?
No. The analysis found changes in blood measures that may be relevant to anemia, but it did not establish that the medicines improve anemia symptoms or replace conventional anemia treatment.
Why might hemoglobin and hematocrit rise?
The review found higher erythropoietin levels and changes in ferritin and transferrin saturation alongside the increases. The authors said this pattern may indicate effects on red blood cell production and iron metabolism, but direct measurements needed to confirm the mechanism were not available.
Could higher hemoglobin or hematocrit pose a risk?
The authors cautioned that further increases could potentially raise thromboembolic risk among people who already have elevated levels. The report does not quantify that risk or establish how it should guide care for a particular patient.
Should patients change their medication because of these findings?
The results do not provide a reason for patients to stop or change a prescribed SGLT2 inhibitor on their own. Anyone concerned about blood counts or treatment should discuss the findings with their clinician.
Source: rss
